비스테로이드성 항염증제 시장 : 질환별, 약물별, 투여 경로별, 유통 채널별 - 세계 예측(2025-2030년)

The Non-steroidal Anti-inflammatory Drugs Market was valued at USD 21.71 billion in 2023, expected to reach USD 23.24 billion in 2024, and is projected to grow at a CAGR of 7.53%, to USD 36.10 billion by 2030.

Non-steroidal Anti-inflammatory Drugs (NSAIDs) are a class of medications used to alleviate pain, decrease inflammation, and reduce fever by inhibiting cyclooxygenase enzymes. These drugs are essential in managing conditions like arthritis, muscular pain, and headaches. The application scope of NSAIDs spans over-the-counter use for mild to moderate pain relief and prescription use for chronic inflammatory diseases. The end-use scope primarily includes healthcare facilities, retail pharmacies, and individual users. Key growth factors influencing the NSAID market include increasing prevalence of chronic pain conditions, an aging population, and heightened awareness of pain management options. Moreover, advancements in drug formulations that minimize gastrointestinal side effects and elevate the efficacy of NSAIDs present noteworthy market opportunities. Innovations like topical NSAID forms and combination therapies serve as potential avenues for business growth and expansion.

However, market growth faces limitations, notably due to the side effects of NSAIDs, such as gastrointestinal bleeding and cardiovascular risks, which can deter usage and lead to stringent regulatory scrutiny. Additionally, the advent of alternative therapies like biologics for inflammatory conditions poses competition to NSAIDs. For companies aiming to capitalize on NSAID market opportunities, focusing on developing safer formulations, such as those with improved gastrointestinal safety profiles or selective COX-2 inhibitors, can be advantageous. Expanding research into personalized medicine approaches that tailor NSAID therapies to individual genetic profiles can also offer a competitive edge. The nature of the NSAID market is highly competitive, with major pharmaceutical companies investing heavily in product differentiation and market penetration strategies. Continued surveillance of regulatory pathways and patient compliance patterns is crucial for maintaining growth momentum. Engaging in strategic partnerships and collaborations for product innovation can be instrumental. In conclusion, while NSAIDs remain a cornerstone in pain and inflammation management, addressing safety concerns and exploring novel drug-delivery systems will be paramount in harnessing market potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Non-steroidal Anti-inflammatory Drugs Market

The Non-steroidal Anti-inflammatory Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rise in chronic pain cases and surge in inflammation cases
  • Increasing geriatric population and rising awareness about the use of non-steroidal anti-inflammatory drugs
  • Increasing preference of people for nsaids over opioids
• Market Restraints
  • Side effects associated with the use of non-steroidal anti-inflammatory drugs
• Market Opportunities
  • Quick authority approvals by the governments and increase in government initiatives
  • Emerging technology, research and development activities, and launch of novel drugs
• Market Challenges
  • Failure of drug during the clinical trial

Porter's Five Forces: A Strategic Tool for Navigating the Non-steroidal Anti-inflammatory Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Non-steroidal Anti-inflammatory Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Non-steroidal Anti-inflammatory Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Non-steroidal Anti-inflammatory Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Non-steroidal Anti-inflammatory Drugs Market

A detailed market share analysis in the Non-steroidal Anti-inflammatory Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Non-steroidal Anti-inflammatory Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Non-steroidal Anti-inflammatory Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Non-steroidal Anti-inflammatory Drugs Market

A strategic analysis of the Non-steroidal Anti-inflammatory Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Non-steroidal Anti-inflammatory Drugs Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Assertio Therapeutics, Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, GlaxoSmithKline PLC, Iroko Pharmaceuticals Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Perrigo Company PLC, Pfizer Inc., Reckitt Benckiser Group PLC, Sanofi S.A., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Non-steroidal Anti-inflammatory Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease Indication, market is studied across Arthritis, Migraine, and Ophthalmic Diseases.
• Based on Drugs, market is studied across Over-the-counter Drugs and Prescription. The Over-the-counter Drugs is further studied across Aspirin (Bufferin, Bayer, & Excedrin), Ibuprofen (Advil, Motrin, Nuprin), Ketoprofen (Actron, Orudis), and Naproxen (Aleve). The Prescription is further studied across Daypro, Indocin, Lodine, Naprosyn, Relafen, Vimovo, and Voltaren.
• Based on Route of Administration, market is studied across Oral and Parenteral.
• Based on Distribution Channel, market is studied across Drug Store, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in chronic pain cases and surge in inflammation cases
    • 5.1.1.2. Increasing geriatric population and rising awareness about the use of non-steroidal anti-inflammatory drugs
    • 5.1.1.3. Increasing preference of people for nsaids over opioids
  • 5.1.2. Restraints
    • 5.1.2.1. Side effects associated with the use of non-steroidal anti-inflammatory drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Quick authority approvals by the governments and increase in government initiatives
    • 5.1.3.2. Emerging technology, research and development activities, and launch of novel drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Failure of drug during the clinical trial
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Non-steroidal Anti-inflammatory Drugs Market, by Disease Indication

• 6.1. Introduction
• 6.2. Arthritis
• 6.3. Migraine
• 6.4. Ophthalmic Diseases

7. Non-steroidal Anti-inflammatory Drugs Market, by Drugs

• 7.1. Introduction
• 7.2. Over-the-counter Drugs
  • 7.2.1. Aspirin (Bufferin, Bayer, & Excedrin)
  • 7.2.2. Ibuprofen (Advil, Motrin, Nuprin)
  • 7.2.3. Ketoprofen (Actron, Orudis)
  • 7.2.4. Naproxen (Aleve)
• 7.3. Prescription
  • 7.3.1. Daypro
  • 7.3.2. Indocin
  • 7.3.3. Lodine
  • 7.3.4. Naprosyn
  • 7.3.5. Relafen
  • 7.3.6. Vimovo
  • 7.3.7. Voltaren

8. Non-steroidal Anti-inflammatory Drugs Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral

9. Non-steroidal Anti-inflammatory Drugs Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Drug Store
• 9.3. Hospital Pharmacy
• 9.4. Online Pharmacy
• 9.5. Retail Pharmacy

10. Americas Non-steroidal Anti-inflammatory Drugs Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Non-steroidal Anti-inflammatory Drugs Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Non-steroidal Anti-inflammatory Drugs Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Apotex Inc.
• 2. Assertio Therapeutics, Inc.
• 3. AstraZeneca PLC
• 4. Bayer AG
• 5. Boehringer Ingelheim International GmbH
• 6. Eli Lilly and Company
• 7. GlaxoSmithKline PLC
• 8. Iroko Pharmaceuticals Inc.
• 9. Johnson & Johnson Services, Inc.
• 10. Merck & Co., Inc.
• 11. Perrigo Company PLC
• 12. Pfizer Inc.
• 13. Reckitt Benckiser Group PLC
• 14. Sanofi S.A.
• 15. Teva Pharmaceutical Industries Ltd.